Key result
FDG PET correctly indicated tumor recurrence in 10 patients with adrenocortical carcinoma, though false-negative findings occurred with very small lesions.
Why the study?
Does FDG PET accurately detect recurrent or metastatic adrenocortical carcinoma in patients with suspected recurrence?
Population
12 patients with known adrenocortical carcinoma who underwent FDG-PET imaging for suspected recurrence or…
Comparison
[F]fluorodeoxyglucose positron emission tomography vs Other imaging findings, clinical features, and…
Design
Case_series
Authors
Loading...
FDG PET may detect recurrent adrenocortical carcinoma but risks false negatives; leaves open its routine role pending prospective validation.
Observational (n=12)
Yes
Does FDG PET accurately detect recurrent or metastatic adrenocortical carcinoma in patients with suspected recurrence?
FDG PET is a useful imaging modality for visualizing most recurrent or metastatic adrenocortical carcinomas, though it may miss very small lesions.
Mackie et al. (2006) conducted an observational in recurrent or metastatic adrenocortical carcinoma (n=12). [(18)F]fluorodeoxyglucose positron emission tomography (FDG PET) vs. other imaging findings, clinical features, and histopathology or clinical follow-up was evaluated on FDG activity, other imaging findings, and clinical features. FDG PET correctly indicated tumor recurrence in 10 patients with adrenocortical carcinoma, though false-negative findings occurred with very small lesions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: